ÖпÆÔº£¬Î人´óѧDiabetes·¢ÏÖ¸ÎÔàÖ¬ÖÊ´úллúÖÆ
¡¡5ÔÂ3ÈÕ£¬¹ú¼ÊѧÊõÆÚ¿¯Diabetes ÔÚÏß·¢±íÁËÖйú¿ÆÑ§ÔºÉϺ£ÉúÃü¿ÆÑ§Ñо¿ÔºÓªÑø¿ÆÑ§Ñо¿Ëù¹ù·Ç·²×éµÄÑо¿ÂÛÎÄ£ºA novel function of hepatic FOG2 in insulin sensitivity and lipid metabolism via peroxisome proliferator-Activated Receptor Alpha¡£¸ÃÑо¿·¢ÏÖ¸ÎÔàFOG2ͨ¹ýÓ°ÏìppAR¦Á±í´ïµ÷½ÚÒȵºËØÃô¸ÐÐԺ͸ÎÔàÖ¬ÖÊ´úлµÄÖØÒª×÷Óã¬Îª¶þÐÍÌÇÄò²¡ÒÔ¼°Ö¬·¾¸ÎµÄ·¢²¡»úÖÆ¼°ÖÎÁÆÌṩÁËеÄÀíÂÛ»ù´¡ºÍ˼·¡£
½üÄêÀ´£¬Ëæ×ÅÉú»î·½Ê½ºÍÒûʳ½á¹¹µÄ¸Ä±ä£¬¶þÐÍÌÇÄò²¡ºÍ·Ç¾Æ¾«ÐÔÖ¬·¾¸ÎµÄ·¢²¡ÂÊÖðÄêÔö¼Ó£¬¶þÐÍÌÇÄò²¡ºÍ·Ç¾Æ¾«ÐÔÖ¬·¾¸ÎµÄ·¢Éú»áµ¼Ö¶àÖÖ´úлÐÔ¼²²¡µÄ²úÉú£¬ÑÏÖØÎ£º¦ÈËÀàµÄÉúÃü½¡¿µ¡£ÒȵºËصֿ¹ÊǶþÐÍÌÇÄò²¡µÄÖØÒª²¡ÀíÌØÕ÷£¬¶øÒȵºËصֿ¹ÓÖºÍÖ¬ÖÊ´úлµÄÒì³£Ãܲ»¿É·Ö¡£Ä¿Ç°£¬¹ØÓÚÒȵºËصֿ¹µÄ¾ßÌå·Ö×Ó»úÖÆ²¢²»Ê®·ÖÇå³þ¡£FOG2×÷Ϊһ¸öÖØÒªµÄת¼¹²µ÷½ÚÒò×Ó£¬ÆäÔÚѪ¹ÜÉú³É¡¢·¢Óý·½Ãæ·¢»Ó×ÅÖØÒªµÄÉúÎïѧ×÷Óã¬È»¶øÆäÔÚÒȵºËØÃô¸ÐÐÔºÍÖ¬·¾¸Î·½ÃæµÄ×÷ÓÃĿǰ»¹´Óδ±»±¨µÀ¡£
¹ù·Ç·²Ñо¿×é·¢ÏÖ£¬FOG2ÔÚdb/dbСÊó£¨ÒȵºËصֿ¹Ä£ÐÍ£©¸ÎÔàÖбí´ïÏÔÖøÉϵ÷£¬Í¨¹ýβ¾²Âö×¢ÉäÏÙ²¡¶¾¼¼ÊõÏòdb/dbСÊóÖÐ×¢ÉäFOG2¸ÉÈÅÏÙ²¡¶¾¿ÉÒÔÏÔÖø»º½âСÊóµÄÒȵºËصֿ¹£¬Ìá¸ßÒȵºËØÃô¸ÐÐÔ£¬¶øÔÚÒ°ÉúÐÍСÊóÖÐ×¢Éä¹ý±í´ïFOG2ÏÙ²¡¶¾ÓÖ¿ÉÒÔÏÔÖø½µµÍСÊóµÄÒȵºËØÃô¸ÐÐÔ¡£½øÒ»²½µÄÑо¿±íÃ÷£¬Ò°ÉúÐÍСÊóÖнµµÍFOG2»áµ¼Ö¸ÎÔàÖ¬ÖʵÄÏÔÖø»ýÀÛ£¬¶ø¹ý±í´ïFOG2¿ÉÒÔÏÔÖø¼õÉÙ¸ÎÔàÖ¬ÖʵĻýÀÛ¡£ÉîÈëµÄ»úÖÆÌ½Ë÷·¢ÏÖ£¬FOG2ÊÇͨ¹ýNR2F2½éµ¼£¬Ó°ÏìppAR¦ÁµÄ±í´ïÀ´Ó°ÏìСÊóµÄÒȵºËØÃô¸ÐÐÔ¼°¸ÎÔàÖ¬ÖÊ´úл¹ý³Ì¡£
¸ÃÑо¿Ö¤Ã÷ÁËFOG2ÔÚµ÷½ÚÒȵºËØÃô¸ÐÐÔºÍÖ¬ÖÊ´úл·½ÃæµÄÖØÒª×÷Óã¬ÓÐÖúÓÚ¼ÓÉîÈËÃǶÔÓÚ¶þÐÍÌÇÄò²¡ºÍÖ¬·¾¸Î·¢²¡»úÖÆµÄÀí½â£¬ÎªÖÎÁƶþÐÍÌÇÄò²¡ºÍÖ¬·¾¸ÎÌṩҩÎï°Ðµã¡£
¸ÃÑо¿¹¤×÷µÃµ½ÁËÎ人´óѧ½ÌÊÚÁõÓµÄÖ§³ÖºÍ°ïÖú£¬²¢»ñµÃ¹ú¼Ò×ÔÈ»¿ÆÑ§»ù½ð¡¢¿Æ¼¼²¿ÒÔ¼°ÖпÆÔºµÈ¿ÆÑлù½ðµÄÖ§³Ö¡£
ÔÎÄÕªÒª£º
A novel function of hepatic FOG2 in insulin sensitivity and lipid metabolism via peroxisome proliferator-Activated Receptor Alpha
Friend of GATA 2 (FOG2) is a transcriptional co-factor involved mostly in cardiac function. The aim of our current study is to investigate the role of hepatic FOG2 in insulin sensitivity and lipid accumulation. Here, we showed that FOG2 over-expression by adenovirus expressing FOG2 (Ad-FOG2) significantly attenuates insulin signaling in hepatocytes in vitro. Opposite effects were observed when FOG2 was knocked down via adenovirus expressing small-hairpin RNA for FOG2 (Ad-shFOG2). Furthermore, FOG2 knockdown by Ad-shFOG2 ameliorated insulin resistance in leptin receptor-mutated (db/db) mice and FOG2 over-expression by Ad-FOG2 attenuated insulin sensitivity in C57/BL6J wild-type (WT) mice. In addition, Ad-FOG2 reduced whereas Ad-shFOG2 promoted hepatic triglyceride (TG) accumulation in WT mice under fed or fasted conditions, associated with increased or decreased hepatic peroxisome proliferator activated receptor ¦Á (ppAR¦Á) expression, respectively. Moreover, the improved insulin sensitivity and increased hepatic TG accumulation by Ad-shFOG2 were largely reversed by adenovirus expressing ppAR¦Á (Ad-ppAR¦Á) in WT mice. Finally, we generated FOG2 liver-specific knockout mice and found that these mice exhibit enhanced insulin sensitivity and elevated hepatic TG accumulation, which were also reversed by Ad-ppAR¦Á. Taken together, our results demonstrate a novel function of hepatic FOG2 in insulin sensitivity and lipid metabolism via ppAR¦Á.